Abstract：
Calcitonin gene-related peptide (CGRP) inhibitors, in the form of injectable monoclonal antibodies, are a newer class of drugs for the prevention of migraine headaches. In clinical trials, they have been found to be effective with good tolerance and few adverse effects. Alopecia has been increasingly noted as a post-marketing event associated with CGRP inhibitor injectables. Of the case reports available on this topic, alopecia has commonly been localised to the scalp and associated with erenumab use; however, not as much has been reported for fremanezumab nor for injection site-related alopecia. We report an occurrence of persistent lower extremity localised injection site alopecia in a patient within our headache clinic who used fremanezumab. The possible mechanism of alopecia may be related to the failure of hair follicle immune privilege in the absence of CGRP immunomodulatory effects.
摘要：
降钙素基因相关肽（CGRP）抑制剂，以可注射的单克隆抗体的形式，是一类新的预防偏头痛的药物。在临床试验中,已发现它们有效，耐受性好，副作用少。脱发已被越来越多地注意为与CGRP抑制剂注射剂相关的上市后事件。在关于这一主题的案例报告中，脱发通常位于头皮，并与erenumab使用相关;然而，关于fremanezumab和注射部位相关性脱发的报道并不多.我们报告了在我们的头痛诊所内使用fremanezumab的患者中持续下肢局部注射部位脱发的发生。脱发的可能机制可能与缺乏CGRP免疫调节作用的毛囊免疫特权失败有关。
